UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 22

of 'Toxicities associated with checkpoint inhibitor immunotherapy'

22
 
 
Ribas A, Hodi FS, et al. KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma (abstract 1216O). Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377.
 
no abstract available